Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Eur J Med Chem. 2018 Mar 06;150:282-291
Authors: Zhao C, Zang J, Ding Q, Inks ES, Xu W, Chou CJ, Zhang Y
Abstract In the past decade, although research and development of histone deacetylase (HDAC) inhibitors as therapeutic agents have achieved great accomplishments, especially in oncology field, there is still an urgent need for the discovery of isoform-selective HDAC inhibitors considering the side effects caused by nonselective HDAC inhibitors. HDAC8, a unique class I zinc-dependent HDAC, is becoming a potential target in cancer and other diseases. In the current study ...